Dr. Raj Shankar Ghosh is a Physician with training in public health. In a career spanning 30 years, Dr Ghosh has focused primarily on infectious diseases and immunization. He has served the National Polio Surveillance Project India of Government of India and World Health Organization as Regional Coordinator of its Southeast Region. As Technical Director at PATH India and Regional Director of JE and VL Projects of PATH, Dr. Ghosh has led multiple projects across countries in Southeast and Western Pacific regions of Asia. He is currently Senior Advisor, Vaccine Delivery at Bill & Melinda Gates Foundation. Dr Ghosh is an honorary Fellow of Indian Public Health Association.

Dr. Pradeep Nagalkar is working as a Head, Quality Control at Haffkine Bio-Pharmaceutical Corp. Ltd. since last 21 years. He is responsible for all Quality Control (Chemical and Biological) related to various Vaccines and Antiseras, Pharmaceutical products like tablets, oral liquids.

Dr. Pradeep Nagalkar has over 34 years’ experience in the biotechnology industry, 21 years of his experience is in vaccine industry.

He has completed his post-graduation from Seth G. S. Medical College & K.E.M. Hospital, Parel, Mumbai. He is Ph.D. in Microbiology from University department of Chemical Technology (UDCT), Mumbai. He has Extensive knowledge of Protein purification and Biological testing. He has worked previously with National Plasma Fractionation Centre, Parel, Mumbai and Biological E., Hyderabad.

Dr. Pradeep Nagalkar is also deputed for various workshops and attended many conferences, symposiums and delivered many lecturers in national and international conferences, written scientific articles.

Presently an Additional Director, Production (viral vaccines) at Serum Institute of India Pvt. Ltd., Pune, India. Trained in regulatory affairs at UMASS in Boston, USA and Chumakov Institute, Moscow, Russia. He is Ex.IITian and has a Doctorate in virology with more than 33 years of rich experience in various departments such as production, quality assurance, quality control in the Biotechnological industry and Research Institute. He has expertise in upstream processing of viral vaccines. He is specialized in purification of viral vaccines and has developed WHO approved Oral polio vaccine and Rabies vaccine at SIIPL.

French/Slovak Medical professional specialised in infectious and Tropical (Neglected) diseases, Internal medicine, certified in Immunology,Pediatry and Public health and diplomacy in Switzerland (IHEID), Vaccines and years of Clinical/Medical practise.

Lived multi-country medical “field “experience in Southeast Asia (India in particular), West/Central/East Europe and Middle East.

Speaking French, English, Italian, Russian, Czech/Slovak.

Over 10 years of experience as consultant/scientific expert and medical lead in pharmaceutical research and development for European and USA companies(Servier, Wyeth/Pfizer,Flamel technologies as global medical lead and medical director of clinical and preclinical development) within various therapeutic areas covering complex international projects.

Supporting research and cooperation around Microbiota/Immunity (certified CIMI Microbiota medical application Paris) Focus on better understanding of host immune system - pathogen-microbiota interactions for adapted intervention in transversal way including joint interest withing infectious diseases /cancer and common targets (e.g viruses/immune-oncology).

Supporting direction of Prevention and Early diagnostic (innovative biomarkers) in clinical practice and Medical care.

Member of international advisory groups (CHD India) and think tank groups in order to foster global cooperation in areas of Public health with Europe.

Speaker at various international conferences and Member of administrative boards of French academia (WAAR- antibiotic resistance, French immunology society).

Years of expertise to work globally but more focused on Asia(India in particular) and broader Eurasian cooperation as a Medical advisor bringing new innovative concepts alive and getting them endorsed.

Dr. Rajendar Burki is currently working as AVP, at R&D, Biological E Limited. Heading Analytical, Glyco-Conjugation and Formulation development activities.

He received Ph.D. degree in Bioanalytical/Biological Chemistry from Tohoku University (Japan), followed by postdoctoral training at University of Alabama at Birmingham (USA).

Authored 10 patents, 20+ international publications and delivered talks in National and international conferences.

His expertise includes Analytical development and characterization, conjugation of biomolecules with markers and polysaccharides including process development of biopharmaceuticals.

Dr Sudeep Kumar did his Post Doc in Biotech from Valencia. He has more than 20 years of experience in Biopharma from Large scale fermentation based product to recombinant therapeutic proteins, Vaccines and Diagnostic kit. He has vast experience from R&D to commercialization of recombinant proteins, Vaccines and Diagnostic kit with good understanding of regulatory requirement.

He has worked from R&D to tech transfer and manufacturing of different molecule. During his tenure he was involved in dealing with different regulatory agencies for approval and faced WHO, USFDA and other regulatory audits. He also actively involved with clinical research team for Preclinical and clinical trials of recombinant proteins and vaccine. He developed and commercialized many recombinant proteins, vaccines and rapid diagnostic kit.

He established the VLP technology platform for different vaccine in India in collaboration with Novavax and taken the approval for this new concept technology. He is actively involved in the development of novel therapeutic protein for cancer therapy.

He has worked with Ranbaxy, Cadila pharma, Unichem and now at present he is working as Senior Vice president at Biological E, Hyderabad.

Annu Uppal is currently working as Associate Director- Scientific Affairs at United States Pharmacopeia (USP)-India. In her role, she is leading the USP’s initiative of Knowledge hub for Multi Attribute Methods (MAM), scientific engagement activities and external collaborations. She is also an approved faculty for USP Education programs and regularly conducts various webinar and education programs.

Annu is core mass spectrometric expert with >15 years of experience in analytical method development, validation, product characterization, impurity profiling, glycan analysis. Before joining USP, she was leading the mass spectrometric applications globally for monoclonal antibodies & other biotherapeutics at SCIEX. Annu was instrumental in setting basic and advanced mass spectrometry-based workflows like glycan profiling, disulfide linkages elucidation, multi attribute methodology, native mode analysis and host cell protein analysis for therapeutic antibodies. She also has expertise in the analysis of peptides, Metabolites, Lipids, Biomarker Discovery/Verification workflows. Annu has more than 30 research papers and book chapters in peer reviewed journals. She has presented in several National and International Conferences as Invited speaker.

Over 30 years of research experience in Vaccine development programs, Technical due diligence, Pilot facility design & execution, Process development, Process validation, Formulation development for thermostable vaccines, Clinical batches manufacturing, cGMP fill finish, Clinical trials, Regulatory filing and approvals. Successfully transferred the manufacturing process for various vaccine candidates from R & D scale to commercial scale.

Served in different capacities at Indian Immunologicals Limited overseeing the process development for various Bacterial & Viral vaccines (Recombinant & Conventional), Conjugate vaccines, Monoclonal antibodies & Bio-therapeutics.

Fields of expertise include Process Development, Formulation Development – Thermostable vaccines, vaccine delivery devices and combination vaccines for Pediatric use.

Prior to joining Indian Immunologicals Limited served as Sr. General Manager, Bio Process Head at Shantha Biotechniques Limited (A Sanofi Company) and as Senior Director at MSD Wellcome Trust Hilleman Labs overseeing analytical and formulation development.

Dr. Vasan Sambandamurthy is Senior Vice President – Strategy & Global Operations at Bugworks Research Inc – a clinical stage biopharmaceutical company that is developing novel class of broad-spectrum antibacterial agents and immunotherapies to treat patients with critical care needs in infection and cancer.

Vasan brings over 20 years of professional experience in vaccine discovery and drug development at major global corporations like Novartis, AstraZeneca, and Biocon. At these organisations he has held senior leadership positions, provided strategic directions, and orchestrated major business operations to develop affordable medicines across multiple therapeutic areas including oncology, diabetes, infectious diseases (specifically against tuberculosis and malaria) and inflammation. Most recently, he was the Chief Executive Officer at the DBT/Wellcome Trust India Alliance, a major global funding agency (annual budget of £24 million) promoting basic, biomedical and clinical research across India. He has over 50 publications in peer-reviewed international journals including Nature Medicine, Nature Immunology, Nature Communications and co-inventor on 4 patents.

Senior biotech executive professional with expertise in viral vaccines with 30yrs experience in vaccine development with focus on CMC, pre-clinical animal studies and clinical studies including clinical samples testing. Currently at PATH, leading and managing projects for vaccines and biologics including product development strategies for compliance with GMP and/or GLP practices as applicable for national and international regulatory framework compliance (WHO, FDA, EMA,DCGI, NMPA). Experience in national regulatory approvals and for achieving WHO pre-qualification for vaccine products. Currently project lead for polio vaccines development and scaleup for OPV and IPV related work. Current and past projects at PATH includes work related to measles-rubella, influenza, RSV, Yellow fever, live rotavirus, and SARS-CoV2 with technologies including whole virion, inactivated, vectored, live attenuated, VLPs and subunit vaccines. Holds national and international patents on VLP technology for influenza and RSV vaccines, and include publications in peer-reviewed journals. Presently serves on several scientific panels for national and international vaccine meetings, also serves as scientific reviewer for manuscripts submitted for publications in journals including Vaccine, Journal of Infectious Diseases, Emerging Infectious Diseases, and Human Vaccines & Therapeutics.

A seasonal professional with three decades of experience of setting stratergies for overall quality operations.

Cultural transformations to achieve compliance with sustained profitability.

Currently Working with Wockhardt ltd as ahead of Global Quality and compliance.

Wockhardt played a very vital role in UK for providing vaccine in coordination with Astrazinica to UK population. This is highly appreciated by PM Mr. Boris Jonson and His Highness Prince chalce by personally visiting the mfg unit and thanking the team of mfg and quality for their contribution for health care during pandemic.

Ms Pradnya has worked with various organisation like Sun Pharma, Ipca laboratories and ACG group gathering experience handing various regulatory agency coordination like US , UK and ROW countries. Her key take away from this organization is handing mergers, acquisitions, optimizing process and products for business continuity.

She is master of science with analytical chemistry and medicinal chemistry . She is certified QMS auditor and EHS auditor from BVQI UK.

Shiv is a scientist turned entrepreneur with over 20 years of global experience in innovative research in immunology, combined with strong business and leadership accomplishments through entrepreneurship.

He is currently the CEO of stealth startup, an immunodiagnostics startup presently focused on the science of COVID-19 immunity elicited via infection or vaccination. The Startup has been involved with COVID-19 vaccine manufacturers, and academic institutions, in establishing and evaluating the cellular immunity to COVID-19. Shiv has spearheaded the establishment of various platforms at the startup that are instrumental in understanding a vaccine’s efficacy in eliciting and sustaining both T and B cell response, and further exploring how these responses are modulated under various booster dose combinations. In addition, the startup developed a simple and rapid, blood-based test that will allow one to test for T cell immunity against COVID-19 without requiring high-end research infrastructure. The test has now been used by vaccine manufacturers to screen study subjects for inclusion in, or exclusion from, a study or clinical trial. These robust and multi-faceted platforms that the startup has developed for the in-depth study of COVID-19 vaccines is easily adaptable to any disease and vaccine, depending on the need of the hour, in an accelerated timeframe.

Shiv’s previous entrepreneurial experience saw him embark on an ambitious mission to build and establish a high-end products and services entity for the UK/US-based Indoor Biotechnologies in the Asia Pacific market for immunology and allergy needs. He served as its executive director for over 6 years and during his highly successful tenure, he developed and marketed a vast portfolio of cuttingedge, innovative solutions in the areas of immunology, allergy, inflammation, immuno-oncology, and anti-viral testing. The company catered to academia and industries involved in the development of biologics, diagnostics and FMCG products.

During his career in academia, Shiv served as a Principal Investigator at the Singapore Institute for Clinical Sciences, where he built and established a new research program to probe the immunobiology of viral diseases leading to the demonstration of the seminal role of the complement system in survival following influenza infection.

Prior to this, Shiv was a recipient of the prestigious Wellcome Trust traveling and research fellowship, leading him to the School of Medicine, Cardiff University, UK, where he identified a unique and previously unknown role for CD59 in augmenting T cell immunity in infection and cancer.

Shiv has an award-winning Ph.D. in Immunology from the esteemed All India Institute of Medical Sciences (AIIMS), New Delhi.

Dr. Ravi Ganapathy has over 29 years of professional work experience in the hospital, biotech research & vaccine industry settings. He has hands-on experience in development, manufacturing of recombinant (bacterial/yeast-derived), bacterial and viral vaccines. Having led R&D, Production and Quality Assurance teams he has an extensive understanding of manufacturing and R&D-related quality & regulatory requirements for commercialization of biotech products, especially vaccines, and the related GLP & GMP documentation. He joined Hilleman Laboratories Singapore as the Director–CMC R&D in April 2022.

Immediately prior to joining HLS, Dr. Ganapathy was `Head–Vaccine Development Department’ at the International Vaccine Institute (IVI), Seoul, South Korea for 3 years from May 2019. There his streamlined the technology transfer processes, vaccine process development activities, process/analytical development for new candidate vaccines, etc.; he also contributed to university education programs as `Adjunct Professor’ to Yonsei University and Seoul National University.

Before IVI Dr. Ganapathy he was with Biological E. Ltd., Hyderabad, India for over 5 years, where he helped set-up laboratories, built and led the Manufacturing Sciences team providing full-fledged support to the commercial manufacturing divisions (production & QC) -including Life-Cycle Management involving the introduction of new delivery systems, and technology transfers. Based on the work done under his leadership at BioE, an international patent involving a novel adjuvant preparation process was published.

Prior to BioE, Dr. Ganapathy worked for 2 years at Shantha Biotechnics (a Sanofi company), where he led the scale-up of the manufacturing process of a tetravalent rotavirus vaccine from Phase-I to Phase-III and oversaw the Ph-III material production and delivery. His first vaccine industry experience, however, was with Bharat Biotech International Ltd. where he worked for >14 years, and also completed his PhD through his work on a CDC-NIH-sourced multi-epitope, recombinant malarial vaccine candidate against Plasmodium falciparum. At BBIL Dr. Ganapathy spearheaded teams on projects for manufacturing vaccines for use in several clinical trials (supported by PATH/BMGF, MVI/EVI and DBT-India) and for commercial supplies. He also played a crucial role in product and process development, and in the approval of the first cell culture-derived Pandemic H1N1 Influenza vaccine in India (2009).

Dr. Ganapathy graduated as a double-gold medalist for his post-graduate work in `Medical Entomology’ from VCRC (ICMR) in 1993; and his bachelor’s degree was in `Medical Laboratory Technology’ from JIPMER (1991), both in Pondicherry, India. He has been a lead- or co-author of 11 research papers and has delivered talks at several international conferences and training programs over the last 15 years.

Dr Vinod Pantula has over 16 years of experience in vaccine development, specializing in preclinical and early clinical development of vaccines. Presently he is working as the Head of Product Development - Vaccines at Dr Reddy's Laboratories Hyderabad, dedicating his time, effort and ability in establishing a vaccine development facility to develop vaccines for unmet need using modern manufacturing platforms.

Dr. Arun Kumar is the Preclinical Vaccines Development Lead at the Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway. The main objective of CEPI is to accelerate the development of vaccines against emerging/re-emerging infectious diseases and enable access to these vaccines for people during outbreaks. Dr. Kumar previously held positions at the GlaxoSmithKline Vaccines & Novartis Vaccines and Diagnostics, where he led vaccine development programs based on the mRNA technology. At CEPI, Dr. Kumar is leading programs focusing on mRNA innovations, preclinical vaccine development and co-leading CEPI Centralized Global Laboratory Network. Dr. Kumar holds a Ph.D. in Viral Immunology and Infectious diseases from the University of Helsinki, Finland.

Dr Subhadra Dravida is the Founder CEO of Transcell group. She will be presenting a Transcell developed revolutionary product (original innovation) named NeuroSAFE - A Next generation, non-animal workstation solution to test predict vaccine safety, adverse events concerns in the conclave. NeuroSAFE developed as an assay system is embedded with AI and ML tools integrating digital platforms with real time microphysiological systems yielding healthy human specific readouts, majorly supporting safe immunization programs in India.

Dr. Arjun Raghuwanshi is currently working as General Manager at Gennova Biopharmaceutical Ltd Pune. Previously he has worked with major Indian biopharmaceutical companies e.g. Intas, Zenotech, and Wockhardt Ltd. to bring 20 years of work experience in the field of downstream process development and manufacturing operations. He has developed novel processes for products like recombinant human insulin, EPO, TNK-tPA, GCSF, PEG GCSF, Peg Asparaginase, Rituximab, Adalimumab and Bevacizumab.

Recently, he has developed a commercial scale process for Linear Plasmid preparation and has been instrumental in developing the purification process for India’s first mRNA vaccine (Gemcovac) for covid-19. In the field of bioprocess development, he has received two global process patents for recombinant GCSF (US 20180223270A1) and TNK-tPA, (US20170210784A1). He has published his research work in the field of malaria and other novel drug candidates in the reputed journals. His research interest includes process development, continuous processing, manufacturing operations, process control, and technological innovations.

Arjun holds a Ph.D. in Biotechnology (SBPPU, Pune), M.Sc. in Biotechnology (DAVV, Indore) and B.Sc. in Biotechnology (Jiwaji University, Gwalior).

Dr. Pragya Dhruv Yadav is Senior Scientist (Scientist-F) & Head of the Biosafety level-4 laboratory, Asia’s first state of the art facility to handle high-risk pathogens at ICMR-NIV, Pune. During COVID-19 Pandemic, she was involved in timely diagnostic support and development of point-of-care assays, Anti-SARS human IgG-antibody ELISA which was used widely in the country for diagnosis. The first three positive samples were identified from Kerala state having a travel history from Wuhan, China. She has expertise in Molecular biology, translational technology, novel pathogen detection, pre-clinical trials, biosafety and biocontainment. She has contributed significantly to shaping up India’s response to the SARS-CoV-2 pandemic by early isolation of the SARS-CoV-2 and fast tracking the development of the indigenous vaccine and demonstrating the efficacy of COVAXIN™ against the different SARS-CoV-2 variants. Besides this, she had also discovered many novel viruses and quickly provided containment responses and diagnosis for Nipah, Zika, CCHF, KFD and Monkeypox virus outbreaks in the country. She has developed many cost-effective diagnosis assays for CCHF, KFDV, and SARS-CoV-2, which are commercialized. Her work contributed significantly to the beginning of research on highly infectious viral pathogens that helped the prevention and control of outbreaks in India. She has discovered many viral etiological agents such as Crimean Congo hemorrhagic fever, Nipah Zika, Tioman, Oya, Malsoor, Catque, Equine encephalosis and Kundal virus for the first time in India. She has led many outbreak investigations and research on CCHF, Kyasanur Forest Disease, Nipah, Zika, SARS-CoV-2 and Monkeypox. Her expertise in the field of BIorisk Management has been useful in strengthening the diagnostic laboratory network (VRDL) across the country. This has helped in preparedness against public health emergencies posed by Ebola, CCHF, Nipah, Yellow fever, SARS-CoV-2 and Monkeypox. Besides this, as a WHO consultant, she assisted in the evaluation and validation of Biosafety level-3 laboratories in Nepal and Bhutan.
She is recipient of many prestigious awards; amongst them few are Bharat Bhagya Vidhata Samman 2022 and ICMR awards [Major General Saheb Singh Sockey Award, Dr. T Ramchandra Rao Award], Dr. Pran Nath Chhuttani Oration Amritsar Award, Dr Vinod Kumar Bhargava Award from (National Academy of Medical Sciences) and Dr. K.M. Bhansali Oration award, felicitated by Governor of Maharashtra , National Academy of Sciences India (NASI) as COVID warrior. She is fellow of National Academy of Agricultural sciences and member of many National and International committee including ICMR, WHO, CEPI etc.

She has published more than 270 research papers in national and international journals with very high impact factors.

A professional holding 18 years of rich experience in Biopharma & process industry. Currently working with Avantor supporting fluid handling technology, handling product management in India while working on innovative fluid handling products & systems. He has been working closely with Biopharma end users in India for the commercial development of fluid handling systems. During his previous instinct Pramod has worked in Steam Engineering & process equipment companies in Technical Sales & Marketing, later switched to product management & innovation role. Pramod graduated with bachelor’s degree in Chemical Engineering & MBA in Marketing.

Currently I am the Director of the Antibody Translational Research Program established under the THSTI-IAVI Partnership program and Principal Investigator at THSTI, Faridabad. I have over 22 years of research experiences in managing, leading and executing research activities in the area of infectious disease biology. Successfully supervised several Ph.D. graduate students and several under graduates and postgraduates – who are suitably placed in their career pathways. As Head of the Division of Molecular Virology at the ICMR-National AIDS Research Institute, ICMR, Pune, successfully steered various National and International Projects primarily through extramural funding as Principal Investigator between 2006-2012. This includes playing a major role in capacity building, establishing, validating and implementing early HIV diagnosis program at different regional laboratories in India with support from the National AIDS Control Organization (NACO), Ministry of Health & Family Welfare, Govt of India and WHO SEARO. I made significant contributions made towards understanding in genetic and functional diversities of HIV-1 clade C the major circulating subtype globally as part of global virus surveillance as part of HIV vaccine R&D and development of monoclonal antibodies as products against HIV & SARS-CoV-2 prevention and treatment. As Director of the IAVI India laboratory at the Translational Health Science & Technology Institute, Faridabad, India I have been leading since 2013, as lead Principal Investigator and lead scientific coordinator a large number of scientific projects funded by national and international funding agencies and also have supervised a number of Senior and Junior Scientists, Postdocs, and technical staffs. I have also established a very large network of strategic partnerships and collaborations from different institutions and hospital settings at national level as well as from international institutions to help drive our research endeavors in a strategic manner. I have published over 60 papers in peer reviewed journals as lead author and am listed as an inventor in 3 international patents awarded and three more that has been filed and received several prestigious awards including DBT National Bioscience Award in 2013 and fellowship grant from the American Foundation of AIDS Research (amfAR) in 2004.

Dr. Tulip Nuwal is the chief commercial officer at OmniBRx Biotechnologies Ltd. He has 12+ years of experience spanning academia and industry. A techno-commercial professional with training in both science and commercial aspects of biotech ventures. In his career, he has donned different hats ranging from lab research to global strategy and operations.

At Omnibrx, he and his team are responsible for bringing the proprietary single-use bioprocessing technology, “CellBRx Bioreactor systems” to the global markets. This technology will enable the vaccine manufacturers to produce vaccines and viral vectors at large scales with ultimate process efficiency and cost effectiveness.

Vinita epitomizes the new generation of women professional entrepreneurs. Born in a middle-class Business family in Ahmedabad, she was educated in the city. She graduated from St. Xaviers College with a major in Biochemistry & Biotechnology, and went on to pursue her MSc in Biotechnology, graduating in 2010. Initially focused on research, as an undergrad she contributed at Xavier Research Foundation. Thereafter she held positions at some of the most prestigious institutes in the country that includes Centre for DNA Fingerprinting and Diagnostics (CDFD, Hyderabad) where she carried out research on Molecular Diagnosis of Cystic Fibrosis under Dr. Ashwin Dalal, Indian Institute of Advanced Research (IIAR, Gandhinagar) understanding CAX (cation) Transporter diversity for nutrition enhanced crops and phytoremediation under Dr. Rajni Nadgauda and Institute of Genomics & Integrative Biology (IGIB, Delhi) understanding host-pathogen interaction in tuberculosis infection with a focus on lipid metabolism under Dr. Sheetal Gandotra. Fascinated by the potential of translational research – implementing hardcore research to benefit real life – she made a switch to the real world – she joined Sigma Aldrich Chemicals Pvt. Ltd at an Executive position. After a brief stint at Imperial Life Sciences, she joined Thermo Fisher about 6 years ago in a Techno-commercial role. Her outstanding performance in the company – not only surpassing her sales targets by 100% year on year – but also being a good team player, straddling across verticals to bring efficiency and deliver results, and creating a culture of support and working together led to her promotions as the Business Development Manager handling Biopharma & Biotech Business across South Asia in the company. Vinita has a well-rounded personality – she was active in debating and elocution, group activities, and was elected as the Miss World of her school in the Millennium year 2000, barely as she had entered her teens. Her vision is to encourage innovation in the exciting field of vaccination, and eventually to place India globally as a leader in the Biotechnology/ Vaccine space.

Having 23 + years’ of experience in global procurement and strategic sourcing along with developing and implementing processes for identifying, evaluating, and selecting potential suppliers and negotiating favourable business terms and service level agreements. Well versed with Overall Procurement, Green / Brown Field Project procurement, Strategic Sourcing for Raw Materials and Packaging Materials, Imports, In-Bound Logistics, Vendor Development, ERP System Implementations; Implement Procurement Policies, Contract Manufacturing Sourcing (CMO’s) for Generic Formulations, New Molecule & ANDA Project Sourcing and various Process/Cost Improvisation projects.

Currently heading Global Procurement with Stelis Biopharma, and, previously worked with various reputed companies, like Biocon Limited, Ajinomoto OmniChem, Torrent Pharma, DCM Shriram group, Nectar Lifesciences and Lupin Limited.

On the Education part, I completed an E-MBA in “Operation & Retail Management” from Nagaland Open University and “Masters in Commerce” from Kanpur University and also did a Certification Course in "Supply Chain Management", from SYMBIOSIS Centre of Distance Learning, Pune.

Dr. Nimesh is heading the Vaccine Immunology Laboratory at the National Institute of Immunology, New Delhi. Dr. Nimesh is a virologist and immunologist by training. His team works in the area of virus immunology, and the programs are at the interface of fundamental and translational immunology. Major focus is to understand the biology of T cells, mainly Tfh cells, in the long-lasting protective immunity after vaccination or virus infection in human. Dr Nimesh received several awards from prominent international societies for his significant and novel contribution in the field of T-cell immunology like European Federation of Immunological Societies, the American Association of Immunologist, the Martin Villar haemostasis global award and the ADVAC Fellow of Merieux foundation, France. Dr Nimesh has successfully established a “human immune monitoring and T-cell immunoassay platform” which has been highly instrumental in the COVID-19 research in the country. Dr Nimesh has contributed several high impact publications in the prominent journals like Science Translational Medicine, Nature Microbiology, Nature Communication, Lancet Infectious Disease, Cell Reports etc. He has international and national patents on application of T cells in immunotherapy and vaccinology domain. Dr Nimesh is also serving as the virus immunology expert in several national and international taskforces related to human health.

Dr Khalid is a medical scientist with expertise in vaccinology and infectious diseases. He is the Chief Scientific Officer at Panacea Biotec, one of the leading vaccine manufacturers from India. Dr Khalid is responsible for overall development of vaccines and biologicals, including a Broadly Protective Beta Corona Virus Vaccine at Panacea. Prior to Panacea, Dr Khalid was Director Clinical R&D at Hilleman Laboratories, he has also worked as a scientist at International Vaccine Institute in Seoul South Korea.

Dr Khalid has studied and practiced medicine in India, followed by graduate education from the University of Texas at San Antonio. He has worked in academic, non-profit and commercial entities. He has authored several publications, patents and received several grant funding from major funding agencies like EDCTP, BMGF, H2020 and CEPI. Dr Khalid has collaborated with and worked in several countries across Asia, Africa, and Europe. Dr Khalid is passionate about promoting health for all by reducing inequity in vaccine access.

Panacea Biotec group (henceforth referred as Panacea Biotec) monitors email communications sent to and from Panacea Biotec in order to protect Panacea Biotec, our employees, customers, suppliers and business partners, from cyber threats and loss of Panacea Biotec Information. Panacea Biotec monitoring is conducted with appropriate confidentiality controls and in accordance with local laws and after appropriate consultation. This email (and any attachments or links within it) may contain information that is confidential, legally privileged or otherwise protected from disclosure. The sender confirms that Panacea Biotec shall not be responsible if this email message is used for any indecent, unsolicited or illegal purposes, which are in violation of any existing laws and the sender shall at all times indemnify Panacea Biotec of any civil and/ or criminal liabilities or consequences. While Panacea Biotec has taken reasonable steps to ensure that this email and any attachments thereto are free from computer viruses and the like, it does not undertake any responsibility for loss or corruption of recipient’s data during transmission. Before opening any email, the recipient should ensure that data is free from any viruses.

Dr. Shraddha Bhange is a doctor by profession with more than 10 years of experience in pharmacovigilance. She is currently serving as Medical Director and heading pharmacovigilance team of physicians at EVERSANA . She was recently selected as top 10 Medical officers 2022 and her story is featured on cover page of "Women Entrepreneur Magazine".

She has worked in core pharma companies such as NOVARTIS, Wockhardt, AB Science (French Biopharma based in PARIS) and CRO/IT like Cognizant.

She has worked in India and Europe (Paris) and faced various regulatory inspections and worked in various therapeutic areas such as vaccine, oncology, diabetics, neurology, and generics. She has worked on postmarking and phase I to phase III drugs and supported product approvals in US, Europe and India. Shraddha is skilled in various regulatory/health agency regulations, especially USFDA, EMA, MHRA, and DCGI. Her other areas of interest are medical communications, quality assurance, regulatory requirements, audits and inspections.

Dr. Bhange earned her Bachelor of Medicine and Bachelor of Surgery (MBBS) from the Maharashtra University of Health Sciences (MUHS) under the Medical Council of India (MCI), and completed a specialized postgraduate full time program in paraclinical subjects, Msc Biomed tech from Coventry University, United Kingdom.

Having 15 years of rich reefer industry experience in Reefer Container Manufacturing and cold chain transportation. Techno commercial mind well versed with market, competition and trends give edge to identify an opportunities , forecast and design strategy to achieve the set targets and gain desired market share.

Over 30 years of varied experience Approx 27 years of experience with cargo logistics companies transporting shipments by air and surface cargo Core competency in Domestic movement Over a decade of association with SD Cargo.

Manjunath Dudhanikar is managing applications at M R Sanghavi & Co (JNC). He has 12+ years of rich experience as downstream process professional for cost effective and continuous manufacturing process development & scale up. He has previously worked with Serum Institute of India, GE Healthcare (now Cytiva) and Wockhardt. A techno-commercial professional with experience in both process intensification and commercial aspects of manufacturing. In his career, he has developed, scaled up & troubleshooted various purification process for large number of biomolecules.

At M R Sanghavi & Co, he and his team are responsible for bringing the chromatography purification technology, resins, columns & systems to the commercial markets to enable the manufacturers to purify vaccines & all other biomolecules at large scales with ultimate process efficiency, increased productivity and cost effectiveness.

Manjunath holds a Masters in Bioprocess Technology (ICT, Mumbai), and B. Pharmacy degree (Govt. College of Pharmacy Karad).

Mohana Subramanian completed his bachelor's degree in Veterinary Science and Master’s in Animal Biotechnology from Madras Veterinary college. He got his PhD in Biotechnology from JNTU, Hyderabad.

He started his research career at Indian Immunological limited, Hyderabad. He was group leader of Virology team in R&D center of IIL. Subsequently, he joined the DBT platform called Translational Research Platform for Veterinary Biologicals (TRPVB) as Scientist. Then he worked as head, viral vaccine development programs in Biological E Ltd, Hyderabad. Currently, he is working as Associate director, R&D, Reliance Life Sciences, Mumbai.

During his 20 years of research and Industry career, he had published more than 40 research articles in peer reviewed International Journals, authored two books, filed 6 patents and developed several products.

Membership and Honors

• Farmer Member, Review Committee on Genetic Manipulation (RCGM), Department of Biotechnology, GoI. (From April 2014 to August 2016)
• Convener, Subcommittee for drafting the protocol for conducting clinical trials in veterinary biologicals and drugs, Department of animal husbandry and dairying, GoI
• Member, expert working group for ‘Veterinary products’ in Indian Pharmacopeia, Ministry of Health and Family Welfare, GoI.

Dr. Dharmendra Raghuwanshi is currently working in MSAT group at Serum Institute of India Pvt Ltd (SIIPL). At SIIPL he is involved in various projects; including novel vaccine delivery systems, process development and formulation.

He completed Ph.D. in Pharmaceutical Sciences at University of Alberta (Canada) with specialization in novel vaccine delivery systems for SARS CoV 1 and avian influenza (H5N1) antigens to target dendritic cells. After doctorate he continued working as postdoctoral fellow at University of Alberta, where he explored synthetic glycoconjugate and glycoengineered vaccines, tolerogenic vaccine formulations against peanut allergens and strategies to reduce drug induced anti-PEG antibodies.